Introduction
Approximately 15% of couples are infertile with males and females equally suffering from infertility (Filipponi and Feil, 2009 ). Despite a significant improvement in the diagnostic work-up of infertile men, the cause of abnormal spermatogenesis in about half of all cases remains poorly understood (Forti and Krausz, 1998; Guzick et al., 2001; Dohle et al., 2005) . A significant proportion of idiopathic male infertility is accompanied by severe oligozoospermia or azoospermia which is defined as very few or a complete absence of spermatozoa in an ejaculate. Azoospermia is present in 15% of infertile patients (Jarow et al., 1989) , but unraveling the cause underlying such azoospermia remains a clinical challenge. The current clinical diagnostic methods for non-obstructive azoospermia (NOA) cases are indeterminate and often require surgical intervention for a conclusive diagnosis. However, a minimally invasive technique, e.g. the fine-needle aspiration, often provides limited samples for cytological and histologic diagnosis as well as for gene expression studies evaluating etiology and epigenetics (Huang et al., 2009) . Since infertile patients may have a fear of impairment caused by biopsy or puncture, invasive methods are not widely accepted. Therefore, approaches that are more reliable and noninvasive are needed for the diagnosis of NOA. Several compounds, such as glycerophosphorylcholine, acid phosphatase and a-glucosidase, have already been used as diagnostic indicators for evaluating the male reproductive system. Unfortunately, few of these markers have been proved to be highly specific and sensitive for diagnostic purposes.
Recently, alterations in the expression of microRNAs (miRNAs) in both human and animal models have been linked to many forms of disease (Slack and Weidhaas, 2008; Braig et al., 2010; Gaughwin et al., 2011; Nguyen et al., 2011) . miRNAs are a novel class of singlestranded non-coding RNA molecules of 21 nucleotides in length, which regulate gene expression at the post-transcriptional level by binding to the 3 ′ untranslated region of target mRNAs and causing translational inhibition and/or mRNA degradation (Ambros, 2004; Bartel, 2009 ). They are highly conserved among species, and play critical roles in a variety of biological processes, including development, differentiation, cell proliferation and apoptosis. miRNAs are highly stable and abundant in plasma, serum, seminal plasma and other body fluids. Becasue they are implicated in a wide range of cellular processes, their deregulation can lead to diverse diseases (Gartel and Kandel, 2008; Latronico et al., 2008; Papagiannakopoulos and Kosik, 2008; White and Yousef, 2010; Zampetaki et al., 2010; Baraniskin et al., 2011; Ramon et al., 2012) . Growing evidence has revealed that miRNAs are also involved in spermatogenesis (Ro et al., 2007; Yan et al., 2007; Hayashi et al., 2008; Lian et al., 2009; Krawetz et al., 2011) . Consistent with the potential importance of miRNAs in spermatogenesis, these previous studies which have indicated that seminal plasma miRNAs (sp-miRNAs) are differentially expressed in patients with NOA compared with fertile controls, which has opened a new avenue for the study of novel mechanistic, diagnostic and therapeutic aspects of the spermatogenic failure (Lian et al., 2009) . Much interest in recent years has been focused on the applications of miRNAs in prenatal diagnosis, oncology and etiopathology of various human disorders. However, the molecular mechanism of how miRNAs may mediate the pathogenesis of NOA is poorly understood. Considering previous findings with miRNAs in human serum, saliva and cerebrospinal fluid, we believe that sp-miRNAs may represent a new source of noninvasive diagnostic biomarkers for idiopathic infertile males with NOA. In this study, we hypothesized that sp-miRNAs may serve as diagnostic biomarkers for NOA. We therefore systematically screened sp-miRNAs using the TaqMan Low Density Array (TLDA) chips and then conducted individual quantitative reverse transcriptase polymerase chain reaction (qRT -PCR) assays with two independent validation phases. In addition, the levels of aberrantly expressed sp-miRNAs and DNA methylation patterns of the sp-miRNA genes were examined in testicular tissues of five patients with NOA and five fertile controls. Finally, in vitro analyses of three sp-miRNAs, miR-141, miR-429 and miR-7-1-3p were conducted in the GC-2 cell line to investigate their potential roles in spermatogenesis.
Materials and Methods

Subject recruitment and sample collection
This study was approved by the Institutional Ethics Committee of Nanjing Medical University. All activities involving human subjects were carried out under full compliance with government policies and the Helsinki Declaration. A written informed consent was obtained from each participant. Patients with NOA were diagnosed by testicular biopsy. NOA patients with known medical reasons for their infertility including pathologies of the epididymis or vas deferens, cryptorchidism, mumps, varicocele, retrograde ejaculation, chromosomal abnormalities and Y chromosome microdeletions were excluded from the study. The controls were healthy men with normal sperm parameters who had fathered at least one healthy child without assisted reproductive measures during the same period as the cases were recruited in the hospital. Overall, 200 subjects (n ¼ 100 for NOA, n ¼ 100 for fertile control) were included in this analysis. A complete physical examination, including height and weight, was performed, and a questionnaire was used to collect information, including personal background, lifestyle factors, occupational and environmental exposures, sexual and reproduction status, genetic risk factors, medical history and physical activity (e.g. exercise status). After the interview, each subject donated a 5-ml peripheral blood sample, a single spot urine sample and a semen sample. To detect the generalizable signatures of miRNAs for the prediction of NOA, we pooled seminal plasma samples of 20 cases (from Nanjing Medical University Affiliated Nanjing Maternity and Child Health Care Hospital) and 20 controls, respectively and subjected them to TLDA chip screening (human microRNA panel V2.0, Applied Biosystems Inc., CA,USA). We then performed individual qRT-PCR on the above samples to further filter the signals of the screened miRNAs as heterogeneity of the subjects was present. Subsequently, a two-phase validation was conducted to confirm the results from the screening phase. 
Semen analysis
Semen samples were obtained in a private room by masturbation into a sterile wide-mouth and metal-free glass container after a recommended 2-day sexual abstinence. The method for semen analysis was described previously (Wu et al., 2012) . Observation and counting in the semen analysis were processed automatically, with blinding as to the fertility status of the men whose samples were being assessed to avoid bias.
Sample processing and RNA isolation
All study subjects were recruited during the same period, stored under the same conditions and the samples were handled in equal volumes in each experimental step to control any potential bias. Sample processing and total RNA isolation were described previously (Wu et al., 2012) . The concentration and purity of RNA samples were determined by using NanoDrop w ND-1000, and its quality was verified by denaturing agarose gel eletrophoresis.
Seminal plasma miRNA expression profiling
In the screening phase, we performed TLDA analysis to identify differentially expressed miRNAs from the two pooled samples (20 NOA patients versus 20 healthy controls). Megaplex RT reactions and pre-amplification reactions were run according to the manufacturer's protocol, in which 75 ml of 0.1× TE was added to the PreAmp product and a 9 ml diluted PreAmp product was used to run the RT-PCRs by dispensing 100 ml of the PCR reaction mix into each port of the TaqMan MicroRNA array. The pre-amplified product was loaded into TaqMan Array Human Micro-RNA A + B Cards Set v2.0 (Applied Biosystems, CA, USA) enabling simultaneous quantitation of 667 human miRNAs. TaqMan MicroRNA assays were performed on the ABI 7900HT instrument (Applied Biosystems). U6 snRNA (RNU6B; Applied Biosystems) served as an endogenous control. The default PCR procedure was used, and the analysis was performed by using the RQ manager software (Applied Biosystems). DC t was calculated using the following mathematical formula:
Real-time quantitative RT -PCR of mature miRNA
In the validation phases, candidate miRNAs identified by TLDA were further characterized. Complementary DNA (cDNA) was synthetized from total RNA using miRNA-specific primers according to the TaqMan MicroRNA assay protocol (Applied Biosystems). In brief, 1 mg total RNA was reverse transcribed using specific stem-loop RT primers, after which they were amplified and detected using a PCR with specific primers and TaqMan probes as described above. RNU6B (Applied Biosystems) served as an endogenous control. A quantitative real-time PCR was performed in triplicate using an ABI Prism 7900HT (Applied Biosystems). Cycling conditions were as follows: incubation at 508C for 2 min, denaturation at 958C for 10 min, followed by 40 cycles of denaturation for 15 s at 958C and annealing and extension for 1 min at 608C. Fluorescent data were converted to C t measurements by the 7900 SDS system software (Version 2.3; Applied Biosystems). We assigned an equal number of patients and controls on one plate and run the qPCR for target miRNAs and RNU6B simultaneously. The mean C t value was determined from three PCR replicates. The amount of target miRNAs was normalized relative to the amount of RNU6B (DC t = DC tsample − DC tU6 ). Receiver operating characteristic (ROC) curve analysis was performed to determine the specificity and sensitivity of miRNA as a diagnostic biomarker.
Bisulfite sequencing
Genomic DNA was isolated from testicular tissues of patients with NOA and normal controls. The DNA samples were treated and modified with a sodium bisulfite procedure using the EpiTect bisulfite kit (Qiagen, USA), according to manufacturer's instructions. DNA methylation of mir-141, mir-429 and mir-7-1 was analyzed using a bisulfite sequencing PCR (BSP) method. The bisulfite primers for the three miRNA genes were designed using the Methyl Primer Express v1.0 software and are listed in Supplementary data, Table S4 . Each of the DNA samples was amplified by PCR as follows: a PCR reaction mix containing 5 ml of the bisulfite-treated DNA, 0.5 mM each of forward and reverse primers, 200 mM dNTPs, 1× PCR buffer, 1.25 U of Ex Taq Hot Start DNA Polymerase (Takara Bio, Tokyo, Japan) in a total volume of 25 ml. After activation of the polymerase at 958C for 10 min, DNA was amplified in 35 cycles for 30 s at 958C, 40 s at 58.88C (for mir-141 and mir-429) and 51.98C (for mir-7-1) and 1 min at 728C followed by a final extension at 728C for 10 min. Amplified products were purified using the QIAquick gel extraction kit (Qiagen) and cloned into the pCR2.1 vector (Invitrogen Life Technologies Co., USA), and individual clones were sequenced using an M13 reverse primer and an automated ABI Prism 3730xl Genetic Analyser (Applied Biosystems). Approximately 10 different clones from each PCR product were sequenced to analyze the methylation status of the CpG sites (CpGs). The methylation status was analyzed using the BiQ Analyzer software (Bock et al., 2005) .
miRNA target predictions and pathway analysis
Target genes of miRNAs were predicted using the TargetScan (http:// www.targetscan.org). The database for annotation, visualization and microRNA and idiopathic non-obstructive azoospermia integrated screening (DAVID) (http://david.abcc.ncifcrf.gov) was used to provide the functional annotation according to the KEGG database (http:// www.genome.jp/kegg/).
Cell culture, transient transfection of mimics and qRT -PCR of target mRNAs
GC-2 cells were seeded in 24-well plates and cultured in Dulbecco's modified Eagle's medium with 10% fetal bovine serum at 378C under 5% CO 2 atmosphere. Cells were cultured to 50% confluence and transfection was carried out using Lipofectamine 2000 (Invitrogen) with 50 nM of each sp-miRNA mimic or a scrambled negative control (Gene Pharma) according to the manufacturer's instructions. Cells were harvested at 48 h after transfection. Total RNA from cells and testicular tissues were reverse transcribed to cDNA using a transcriptor first-strand cDNA synthesis system for RT-PCR (Takara) according to the manufacturer's protocol. The PCR was performed using the SYBR green master mix (Taraka) in ABI Prism 7900HT (Applied Biosystems) with the gene-specific primers. Primer sequences used are listed in Supplementary data, Table S6 . Each reaction was performed in a 5 ml volume system containing 1 ml cDNA, 0.2 ml of each primer and 2.5 ml FastStart universal SYBR green master mix. The PCR program used was the same as described previously (Shen et al., 2011) . The results were normalized to the level of Gapdh mRNA in the same experiments. Relative expression of target genes was calculated using the equation 2 −DCt in which DC t = DC t(target gene) − DC tGapdh .
Statistical analysis
Differences in demographic and clinical characteristics, and methylation patterns of miRNA genes between NOA patients and controls were evaluated by x 2 tests or Student's t test. Statistical analyses for miRNA expression levels and gene expression levels of putative targets were performed by Mann-Whitney test. The correlation between relative expressions of miR-141, miR-429, miR-7-1-3p and their respective gene methylation status was analyzed using a two-sided Spearman q-test.
To investigate the effectiveness of the three-miRNAs signature for predicting NOA, a risk-score analysis was constructed. The upper 95% reference interval of each miRNA value in controls of the screening phase was set as the threshold to code the expression level of the corresponding miRNA for each sample as 0 and 1 in screening and two validation phases. The risk score of each sp-miRNA was calculated using the weight by the regression coefficient that was derived from the univariate logistic regression analysis of each sp-miRNA. We further assigned each subject a risk-score function according to a linear combination of the expression level of the three sp-miRNAs. For the first validation phase, the risk score ¼ (2.197 × expression level of miR-141) + (0.530 × expression level of miR-429) + (0.765 × expression level of miR-7-1-3p). For the second validation phase, the risk score ¼ (1.956 × expression level of miR-141) + (0.452 × expression level of miR-429) + (2.325 × expression level of miR-7-1-3p). We then presented the frequency tables and ROC curves to evaluate the diagnostic effects of the sp-miRNA profiles and calculated the area under the ROC curves (AUCs) to evaluate the association with NOA.
All statistical analyses were carried out using Stata (Version 9.0, StataCorp, LP), and P ≤ 0.05 was considered to be significant.
Results
Characteristics of the study population
The characteristics of participants are summarized in Supplementary data, Table S1 . The cases and controls were well matched for age, body mass index, smoking and drinking status. The abstinence time and ejaculate volume were also not significantly different between the two groups in all phases (Supplementary data, Table S1 ). The workflow of the study is shown in Fig. 1 .
Detection of seminal plasma miRNAs and their association with NOA
To obtain an expression profile of sp-miRNAs that is specific for NOA, we employed a strategy that included the initial screening by TLDA chips and the validation by qRT-PCR on an individual basis (Fig. 1) . We started the search by comparing the miRNA expression profiles of NOA seminal plasma with those of fertile controls. Of the 667 miRNAs examined, 260 and 272 miRNAs were detected by TaqMan microRNA array in the control group and the NOA group, respectively. In all subjects, 10 sp-miRNAs showed 2 −DCtcase /2 −DCtcontrol . 4 or , 0.25 (i.e. 8-fold)
by the pooled TLDA chip assay (Supplementary data, Table S2 ). Based on both scientific and applicable considerations, we selected sp-miRNAs that had at most a C t value of 35 by TLDA in both the groups for further individual qRT-PCR confirmation. As a result, nine sp-miRNAs were identified and subjected to additional analyses (Supplementary data, Table S3 ).
We next validated the expression of these nine sp-miRNAs by a TaqMan probe-based qRT -PCR assay using seminal plasma samples from the same 20 NOA patients and 20 fertile controls in the screening phase. For each miRNA, we concomitantly tested fertile control and patients with NOA samples in the same qRT -PCR plate to minimize intra-plate variations. As shown in Supplementary data, Table S3 , the levels of eight sp-miRs (i.e. miR-141, miR-141-3p, miR-193a-5p, miR-20a, miR-429, miR-572, miR-590-5p and miR-7-1-3p) were significantly different between the NOA and control groups (Supplementary data, Table S3 ).
We additionally tested the expression levels of these eight sp-miRNAs in two validation phases. Subjects recruited from Huai'an First Affiliated Hospital of Nanjing Medical University and Nanjing Medical University affiliated Wuxi Maternity and Child Health Care Hospital were used for the first and second validation phases, respectively. The seminal plasma expression levels of four sp-miRNAs were significantly different between NOA patients and fertile controls in the samples of the first validation phase (P , 0.001, 0.014, 0.006 and ,0.001 for miR-141, miR-429, miR-193a-5p and miR-7-1-3p, respectively). Furthermore, three sp-miRs were still significantly increased in patients with NOA compared with fertile controls in the second validation phase (P , 0.001, 0.045 and 0.001 for miR-141, miR-429 and miR-7-1-3p, respectively), thus confirming the results obtained from the screening phase and first validation phase. miR-193a-5p was not further analyzed, as the difference in miR-193a-5p expression levels in seminal plasma between NOA and fertile controls was not statistically significance (P ¼ 0.222).
To evaluate the diagnostic value for the profiles of the three sp-miRNAs, we performed a risk-scoring procedure on their datasets. The distribution of sp-miRNAs expression levels and risk scores of the all combined subjects are shown in Fig. 2 . It can be noted that patients with NOA tended to have higher expression levels of the three sp-miRNAs (Fig. 2) . By using the 95% reference interval of each miRNA expression value as a risk score, we constructed the ROC curves and calculated the AUC to assess the sensitivity and specificity for prediction. When the three markers (miR-141, miR-429 and miR-7-1-3p) were utilized to separate the control and NOA groups in the first validation phase, the AUC was 87.7% (sensitivity 87.5%; specificity 75.0%). Similarly, the control and NOA groups in the second validation phase could still be separated by these three markers (AUC: 83.2%; sensitivity: 80.0%; specificity: 72.5%). Multivariate logistic regression analysis showed that combination of the three sp-miRNAs could serve as a potential biomarker to distinguish microRNA and idiopathic non-obstructive azoospermia between NOA and fertile controls with an AUC of 83.3%, sensitivity of 82.5% and specificity 67.5% (Fig. 2) .
Expression levels of the three miRNAs in testicular tissue
The expression of the three sp-miRNAs was examined by a qRT-PCR in five testicular tissues of patients with NOA and five testicular tissues of fertile controls. All three sp-miRNAs were significantly increased in patients with NOA compared with fertile controls (P , 0.001 for all three sp-miRNAs; Fig. 3 ).
Reproducibility of miRNA quantification and stability in seminal plasma
To test the potential of miRNA as a novel biomarker in seminal plasma, we analyzed the reproducibility of measurements in TaqMan qRT-PCR assays. Levels of miR-141, miR-429 and miR-7-1-3p were measured three times in the same seminal plasma samples collected from each of the patients with NOA. For miR-141, the C t values ranged between 26.0 and 27.3; for miR-429, the C t values ranged between 29.3 and 30.2; and for miR-7-1-3p, the C t values are in the range of 29.0 and 31.0.
An important requirement for miRNAs to be used as markers is their stability in seminal plasma samples ex vivo. Therefore, we first investigated the stability of miR-141, miR-429 and miR-7-1-3p in seminal plasma by subjecting specimens to ≤10 freeze-thaw cycles. This treatment resulted in minimal effects on miRNA levels as determined by TaqMan qRT -PCR. Prior reports have suggested that miRNAs in plasma exist in a form that is resistant to intrinsic ribonuclease (RNase) activity (Huang et al., 2009) . To address whether the miRNAs of our interest exist in a form in seminal plasma that is resistant to RNase activity, we measured the levels of miR-141 in seminal plasma specimens after incubation with a commercial RNase. We concluded that the endogenous miRNAs in the seminal plasma are resistant to RNase, which is in line with previous findings with serum and plasma miRNAs (Mitchell et al., 2008) .
Next, we asked whether miRNAs are stable in stored seminal plasma samples. Accordingly, seminal plasma samples collected from five patients with NOA were kept for up to 96 h at room temperature. Expression levels of miRNAs were measured by TaqMan qRT-PCR assays immediately and after 24, 48 and 96 h of storage. The results showed that miR-141, miR-429 and miR-7-1-3p levels in stored seminal plasma specimens are stable over the time tested. In summary, we conclude that miRNAs exist in a stable form in seminal plasma.
Methylation status of the three miRNAs in testicular tissue of NOA
In the human genome, miR-7 is located at three distinct loci: mir-7-1, mir-7-2, mir-7-3. miR-141 and miR-429 are located at a single locus of mir-141 and mir-429, respectively. All of these loci are embedded with CpG islands. The primer sequences and annealing temperatures used for the BSP method are shown in Supplementary data, Table S4 . The methylation profiles of the three miRNA gene loci were obtained from testicular tissues of five patients with NOA and 5 fertile controls (Fig. 4) . A total of 125, 143 and 120 clones were studied for miR-141, miR-429 and miR-7-1, respectively. The sequences analyzed contain 22, 18 and 15 CpGs in miR-141, miR-429 and miR-7-1, respectively. It was found that the percentage of methylation of miR-141 was significantly lower in NOA patients than in fertile controls. It should be noted that a certain degree of hypomethylation in miR-429 and miR-7-1 could also be observed in patients with NOA but was not statistically significant. As for the methylation patterns observed, all of the 22 CpGs in miR-141 were significantly hypomethylated in patients with NOA, while the levels of CpG methylation at locations 1, 3, 6 and 13 in miR-429, and at locations 10 and 12 in miR-7-1 were significantly lower in NOA patients when compared with the corresponding CpGs in fertile controls (Fig. 4) . The global methylation status of miR-141 and miR-429, but not of miR-7-1, were inversely associated with their expression patterns 1 (for miR-141: Spearman r ¼ 20.7818, P , 0.008; for miR-429: Spearman r ¼ 20.6383, P ¼ 0.047; for miR-7-1: Spearman r ¼ 20.1636, P ¼ 0.652).
Expression of the target genes in GC-2 cells
To study the functional significance of miR-7-1-3p, miR-141 and miR-429 over expression, we next sought to identify their target mRNAs. As a result, several hundreds of potential targets were identified. As presented in Supplementary data, Table S5 , six possible pathways were listed with P , 0.001. They were chronic myeloid Figure 3 Expression levels of the three miRNAs in testicular tissues of patients (n ¼ 5) and fertile controls (n ¼ 5). Data are given in Tukey Box plots showing median (2) and mean (+) values. Asterisks denote significant differences from controls (P , 0.05). leukemia pathway, ErbB signaling pathway, neurotrophin signaling pathway, pathways in cancer, insulin signaling pathway and prostate cancer pathway. To test the potential relationship between miRNAs and these predictive target genes, we performed over-expression experiments by direct transfection of miRNA mimics. After transfection of mmu-miR-141, Tgfb2 and Cbl were shown to be downregulated (P , 0.05). Pik3r3 and Rb1 were down-regulated after transfection of mmu-miR-7-1-3p (P , 0.05) (Fig. 5) .
Discussion
Several reports have described that deregulation of miRNAs is tightly linked to human disease (Hu et al., 2010; Li et al., 2011; Revel et al., 2011) . Hence, expression analysis of miRNAs is of increasing interest for diagnostic and prognostic purposes. Because of the simplicity and reproducibility of collecting semen samples, identification of easily testable biomarkers in seminal plasma may have a great potential in the diagnosis of spermatogenic failure. Recent studies by us and others (Wang et al., 2011; Wu et al., 2012) suggest that the unique patterns of sp-miRs may serve as powerful and noninvasive biomarkers for spermatogenic failure. Therefore, the determination of sp-miRNA signatures in patients with NOA by qRT-PCR for assessing the profiles of a small number of miRNAs, as shown in this study, seems to be a clinically applicable procedure.
Following the TLDA screening phase, we tested eight candidate sp-miRNAs in two independent validation phases in NOA patients and fertile controls. The up-regulation of miR-141, miR-429 and miR-7-1-3p detected in seminal plasma from NOA patients compared with fertile controls reached statistical significance in the two independent validation phases. For the first time, we have demonstrated, by TLDA assay-based global miRNA analysis followed by qRT-PCR confirmation, that the expression profiles of specific sp-miRNAs are altered in infertile patients with NOA. Analysis of the characteristics of the combination of the expression levels of seminal plasma miR-141, miR-429 and miR-7-1-3p, yielded high diagnostic sensitivity and specificity, which have proved to be an even more powerful discrimination tool.
miRNAs are essential for early male germ cell proliferation and late spermatogenesis to form functional sperm (Hayashi et al., 2008; Maatouk et al., 2008) . Expression levels of miRNAs are high in primordial germ cells (PGCs), germ cells and germ line stem cells, compared with the levels in somatic cells (Buchold et al., 2010) and the expression of several miRNAs seems to depend upon the developmental stage of the germ cells. Thus, miRNA expression may be completely dependent on which cell types are present in the testis. A very recently published paper demonstrated that miR-141 and miR-429 were significantly up-regulated in sperm, seminal plasma and testicular tissue of patients with impaired spermatogenesis (Abu-Halima et al., 2013) . We found that the expression pattern of the three miRNAs in testicular tissue is coincident with that of seminal plasma. Thus miRNAs in sperm and seminal plasma samples could reveal how far spermatogenesis has progressed. However, future research is needed to examine the expression pattern of miRNAs in different cell types present in testis. This could reveal if sperm is present in the testis, or if it is possible to retrieve cells that could be used for in vitro fertilization. Previous studies have suggested that late meiotic and haploid germ cells are the main source of miRNA production during spermatogenesis (Ro et al., 2007; Guo et al., 2009; Bouhallier et al., 2010) . In mice, the expression of miR141 was down-regulated gradually in male germ cells throughout their development (Hayashi et al., 2008) . Despite the potential importance of miRNAs in spermatogenesis, there have been limited studies on the changes in the miRNA expression profile of germ cells during spermatogenesis. Previous studies using whole testes clearly demonstrated that testicular expression of miRNA molecules changed with the stage of spermatogenesis. miR-141 is mainly expressed in the reproductive system (Landgraf et al., 2007) , with expression in early PGCs and up-regulation from Day 7 to Day 14 in mouse testis (Buchold et al., 2010) . We have found that the three identified miRNAs were highly expressed in the sperm of fertile controls (data not shown). We estimated that secretions from the seminal vesicles, the prostate and the bulbourethral glands make up .90% of the volume of semen and likely represent one source of sp-miRNAs. Additionally, apoptosis of germ cells may be another source. We also confirmed that the three miRNAs are expressed significantly higher in testicular tissues of NOA compared with normal controls. We assumed that the higher expression of such miRNAs in testicular tissue might be an important source of increased sp-miRNAs in patients with spermatogenic failure. Such information will not only be used for identifying novel and noninvasive biomarkers for molecular diagnostics in male infertility, but may also provide mechanistic insight into the spermatogenetic processes that regulate and control fertility. Future research is needed to fully elucidate the sources of miRNAs in seminal plasma.
Recent studies have suggested that some miRNA genes are methylated, and their methylation status could affect miRNA expression (Lopez-Serra and Esteller, 2012) . In this study, we examined whether altered expression of the three sp-miRNAs studied could be the cause of aberrant DNA methylation patterns in the pathogenesis of NOA. We found that aberrant methylation patterns of two of the sp-miRNA genes are strongly associated with their abnormal expression. Our data showed that DNA hypomethylation-mediated activation of miR-141 and miR-429 was a relatively frequent molecular event in patients with NOA, suggesting that epigenetic silencing of these miRNA genes may be associated with spermatogenesis, although further experiments with larger sample sizes will be needed to confirm such findings.
To investigate the potential function of these three sp-miRNAs, we identified 16 of their target genes through TargetScan and DAVID. After overexpressing the three sp-miRNAs in a GC-2 cell line, we found that Pik3r3 and Rb1, which were predicted by miR-7-1-3p and Cbl and Tgfb2, that were regulated by miR-141, were all downregulated by these miRNAs. Rb1, the first identified tumor suppressor, is involved in the regulation of cell cycle progression, DNA replication and terminal differentiation. Of the four target genes, Rb1 is a ubiquitously expressed gene in vertebrate tissues and plays a role in the regulation of cell cycle and apoptotic process. Rb1 was found to parallel the stage-dependent androgen receptor expression in Sertoli cells and might exert effects on spermatogenesis (Tan et al., 2005) . Cbl is highly expressed in the reproductive system and acts as a negative regulator of many signal transduction pathways. Tgfb2 is highly expressed in a variety of human tissues and performs many cellular functions, having a vital role during embryonic development (Tandon et al., 2010) . Pik3r3 is expressed early during development and remains abundant in adult brain and testis tissue, and is detectable in adult adipocytes, heart and kidney tissues (Pons et al., 1995) . These target genes are expressed in the testis and have been suggested to play a critical role in the apoptotic process of germ cells (Konrad et al., 2006; Zhang et al., 2007) . Thus, these data suggest that the involvement of miRNAs in the pathogenesis of NOA might be through the apoptosis pathway. Taken together, our findings support a role for the three identified sp-miRNAs in the pathogenesis of NOA. Besides their effects on cell cycle and apoptosis in spermatogenesis, Rb1, Pik3r3, Cbl and Tgfb2 may also play crucial roles in the origin and development of cancers Campbell et al., 2011; Kang et al., 2012; Kleinerman et al., 2012) .
Numerous miRNAs are exclusively or preferentially produced in the mouse testis (Barad et al., 2004; Ro et al., 2007) . Furthermore, spermatogenesis is retarded in the Dicer-deleted testis at an early stage when proliferation and/or early differentiation of these cells commence before their entry into meiosis, suggesting that miRNAs play important roles in spermatogenesis (Hayashi et al., 2008) . Altered miRNA profiles have been found in the testicular tissues or reproductive cells of infertile patients (Lian et al., 2009; McCallie et al., 2010) . This Figure 5 Expression of predicted target genes after transfecting miRNA mimics in a GC-2 cell line. qRT -PCR analysis showed relative expression levels of target genes after transfecting miR-141 (A), miR-429 (B), miR-7-1-3p (C). Asterisks indicate significant differences in relative expression (P , 0.05). study identified three sp-miRNAs (miR-141, miR-429 and miR-7-1-3p) that were markedly increased in NOA patients, suggesting an important role for miRNAs in male reproductive function, which may be associated with human infertility.
The stability of miRNAs is an important prerequisite for their clinical utility. In our study, we found that sp-miRNAs are stable, resistant to RNases and remain stable even after being subjected to harsh conditions. Therefore, the stability of sp-miRNAs is in agreement with that of serum miRNAs previously reported (Chen et al., 2008; Mitchell et al., 2008) . We propose that the reasons for the remarkable stability of sp-miRNAs are similar to those for serum miRNAs. The stability of sp-miRNAs may partially result from binding of complex organic molecules, and the formation of a RNA-macromolecule complex may represent one mechanism of sp-miRNA protection (Huang et al., 2009) . Moreover, given that secretions from accessory glands make up 90% of the volume of semen, they likely represent other sources of sp-miRNAs. miRNA in high concentrations is more readily isolated than sperm RNA and is likely a better candidate for screening heritable germline epimutations, especially in NOA patients. miRNA also has potential as a replacement biomarker of spermatogenic failure. Such an approach may overcome the possible drawbacks associated with testicular biopsy.
In summary, we have identified a distinctive sp-miRNA signature in idiopathic infertile males with NOA. In particular, we have demonstrated that the profile of three sp-miRNAs with significantly increased expression could serve as an adjunct biomarkers for the diagnosis of male infertility. Additionally, the methylation status of two of three sp-miRNAs was shown to be inversely associated with their expression patterns. Moreover, four predicted target genes were found to be down-regulated by the sp-miRNAs. Taken together, these results provide a novel insight into the molecular mechanisms of male infertility and the clinical value of miRNAs in diagnosing NOA.
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